Madrigal Pharmaceuticals (MDGL) Projected to Post Earnings on Tuesday

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($3.66) per share and revenue of $112.79 million for the quarter.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, topping the consensus estimate of ($4.32) by $1.61. The company had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Up 1.4 %

Madrigal Pharmaceuticals stock opened at $331.29 on Tuesday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $7.31 billion, a P/E ratio of -13.21 and a beta of -0.69. The firm has a 50 day moving average price of $325.67 and a 200-day moving average price of $312.15. Madrigal Pharmaceuticals has a twelve month low of $191.18 and a twelve month high of $377.46.

Analyst Upgrades and Downgrades

MDGL has been the subject of a number of research reports. Citigroup increased their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and set a $443.00 price objective on shares of Madrigal Pharmaceuticals in a report on Thursday, April 24th. HC Wainwright increased their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley raised shares of Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and boosted their price objective for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $409.00.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, VP Robert E. Waltermire sold 14,113 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $341.32, for a total value of $4,817,049.16. Following the completion of the sale, the vice president now owns 3,728 shares of the company's stock, valued at approximately $1,272,440.96. The trade was a 79.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James M. Daly sold 15,470 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the transaction, the director now directly owns 1,912 shares in the company, valued at $664,324.40. This trade represents a 89.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,810 shares of company stock worth $10,610,594 over the last ninety days. Insiders own 22.80% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.